Apellis/Sobi Phase 3 VALIANT meets primary endpoint; 68% proteinuria reduction in C3G/IC-MPGN

Apellis Pharmaceuticals, Inc.

Statistically significant 68% proteinuria reduction vs placebo (p<0.0001) at Week 26.
Key secondary endpoints met: composite renal endpoint and ≥50% proteinuria reduction.
Favorable safety profile; no meningitis or serious infections from encapsulated bacteria.
All VALIANT completers enrolled in long-term extension study VALE.
Apellis to file sNDA with FDA in early 2025; Sobi to submit EMA application in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.